• +613 8892 4854
  • info@immuron.com

    :

Immuron
  • +613 8892 4854
  • info@immuron.com
  • Cart - 0

  • Menu

  • Shop

  • Cart (0)

  • Account
  • About Us
    • About Us
    • Board of Directors
    • Management Team
    • Research Partners
  • Technology
    • Technology Platform
    • Product Pipeline
    • Intellectual Property
    • Production
  • Clinical Insights
    • In vitro studies into SARS-CoV-2 and IMM-124E
    • Travelan US Army results
  • Knowledge Centre
    • Platform Science
    • Product Science
  • Investor Centre
    • Company Media
    • Analysts Reports
    • Corporate Presentations
    • Company Securities Exchange Announcements
    • Capital Structure & Register
    • Corporate Directory and Governance
    • Corporate Contacts
  • Contact Us
  • Products
    • Travelan®
    • Protectyn®
  • About Us
    • About Us
    • Board of Directors
    • Management Team
    • Research Partners
  • Technology
    • Technology Platform
    • Product Pipeline
    • Intellectual Property
    • Production
  • Clinical Insights
    • In vitro studies into SARS-CoV-2 and IMM-124E
    • Travelan US Army results
  • Knowledge Centre
    • Platform Science
    • Product Science
  • Investor Centre
    • Company Media
    • Analysts Reports
    • Corporate Presentations
    • Company Securities Exchange Announcements
    • Capital Structure & Register
    • Corporate Directory and Governance
    • Corporate Contacts
  • Contact Us
  • Travelan®
  • Protectyn®

Categories

  • Products

Information

  • About Us
  • Returns Policy
  • Contact Us
  • Travelan®
  • Protectyn®
  • Home
  • Investor Centre
  • Analysts Reports

Analysts Reports

  • Immuron Equity Report (Oct 2019)

  • Immuron takes aim at the rapid growth of autoimmune diseases

  • Immuron surges 28pc after study shows tablets fight Bali Belly in US soldiers (Jan 2018)

  • Van Leeuwenhoeck Institute Updated Report (Nov 2017)

  • Emerging Biologics in Fatty-Liver and Infectious Disease Management (Sep 2017)

  • BioShares Report - Edition 687 (Mar 2017)

  • Van Leeuwenhoeck Institute Report - Substantial Re-rating in NASH (Feb 2017)

  • Van Leeuwenhoeck Institute Independent Research Note (Jan 2017)

  • SeeThru Equity Analyst Report (Feb 2016)

  • Red Chip C-Difficile Analyst Report (Jan 2016)

  • Red Chip Analyst Report (Aug 2015)

 


Partners

Feature Products 8
Footer Logo 8
Footer 9
Footer Logo 1
Footer Logo 2
Footer Logo 3
Footer Logo 4
Footer Logo 6

Secure Shopping

Fully protected by Incapsula

 

Get Connected

Join our social networks

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Copyright © 2021 Immuron

E-commerce software by Neto

About Us

  • About Us
  • Travelan
  • Protectyn
  • Clinical Insights
  • Contact Us

Information

  • Terms of Use
  • Privacy Policy
  • Returns Policy
  • Security Policy

Payment Options

Contact Information

  • Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
  • Phone: +613 8892 4854
  • Fax: +613 9899 8533